baked studios , formerly baked goods then baked fx , is a boutique visual effects / post-production facility located in culver city , california .

the company provides vfx editorial and color services for the industry ’s top directors , producers , production companies and ad agencies .

baked fx

baked fx <EOT> baked studios / 28 w 44th st . 22nd floor new york , ny 10036

if the selected rigid body is baked , the button label is " unbake " and clicking it removes the keyframes and restores the body to dynamic status .

the modifier interface consists of several rollouts on the modify panel plus a modifier stack with four sub - object levels . most of the controls on this rollout are available only for unbaked rigid bodies and become unavailable once you ' ve baked an object ' s motion . to restore the controls , click the unbake button on the rigid body properties rollout .

since opening its doors in 2005 , baked studios worked with such brands as toyota , disney , lg , and state farm . they have created visual effects for television series like game of thrones , and feature films such as ' now you see me and the final destination . the team has also collaborated with major artists including snoop dogg , rihanna , phish , and justin bieber . the company has won three prime time emmy awards for season 2 , 3 and 4 of game of thrones .

for instance , i can train my 16 - year old daughter to make a lasagna for supper . i give her plenty of time to brown the meat , boil the noodles , mix the cheese and apply the layers . we then put the finished product into the oven to bake and less than an hour later we have a delicious meal . if i asked her to make two lasagnas in the same timeframe , she might be able to do it . if i asked for four or six or more , shortcuts start to get taken , layers get applied sloppily and the baked product is likely to fall short of the first one .

eitht … you referring to the color swatches in houdini ? by default , color correction / gamma was set to 1 . 0 and that makes it non - linear ? … well in a sense of wysiwyg yes , it ' s non - linear since you set your color swatch to color you see on monitor and you want to have the same color in final picture if that setting is 1 , then the color you see on monitor is not the color represented by numerical values set on the color parameter , since monitor has gamma 2 . 2 and therefore changes that color , basically it ' s the same as for textures . so if you set color settings to correct all outputs to 2 . 2 , then you will see the swatch with gamma 2 . 2 applied on top to compensate monitor , which keeps the value of the color parameter linear , because you see directly the color which is represented by numerical values edit : so if you are going to use linear workflow in houdini , set that setting to 2 . 2 ( or whatewer gamma is your monitor ) and keep all checkboxes checked , then the only concern is to make sure all your textures are linear or make them linear in the shader . and if you are not rendering to linear formats ( like exr or other floating point data ) , you can bake in the gamma 2 . 2 to your renders by adding vm _ gamma property to mantra rop , in that case you would need to make sure you are not having gamma set on mplay or render window since it will be already baked in

warning ! to get all of the features imdbpro offers , you must enable javascript .

you can share this page with anyone , including non - imdbpro subscribers . a shared page will expire 7 days after it is first opened .

submit additional information and / or report errors on this page . if it is approved by imdb database managers , it will be added to the page in a future update .

html public " - / / w3c / / dtd xhtml 1 . 0 transitional / / en " " urltoken "

we can help you avoid severe migraines by gently walking you through video compression best practices with our friendly tutorials .

must have a cell phone and daily access to a vehicle . great communication skills and phone skills are a must . we are looking for an upbeat personality , someone who is self - motivated and wants to learn . the ideal candidate would be interested in post production and have a desire to grow in the industry . this position has a high potential for growth in visual effects and post production . previous admin and industry experience preferred .

© 2018 creative cow ® all rights are reserved . privacy policy [ top ]

3750 robertson blvd , ste 204 ( 311 . 71 mi ) culver city , california 90232

turning 30 frames - per - second video into 240 frames - per - second slow - motion using ai technology .

this page is based on a wikipedia article written by authors ( here ) . text is available under the cc by - sa 3 . 0 license ; additional terms may apply . images , videos and audio are available under their respective licenses .

hi all , hope this dont sound silly . i understand users define what 1 houdini unit is , can be in metres , centimeters and so on . say i have a prop with a diameter of 5cm , a sphere have a radius of 0 . 025 which makes it insanely tiny . is this going affect the lighting , texturing or rendering process , is it be advisable to treat 1 houdini unit as 1cm instead to work with bigger props within the viewport ? another doubt is shown inside the viewport , i highlighted 2 boxes on the construction grid is equals to 1 houdini unit - am i wrong ? please ! : ? eitht .

as long as you don ' t have to deal with matching real world ' s focal lengths / disctances , or exchange data with other apps were it could matter , the only thing i know of that ' s more or less scale - dependend in h is : dops and pops this doesn ' t mean , you can ' t work with other scales , but it ' s much easier , because standard values ( e . g . gravity ) , parts of the tools shelf , … are optimized for 1 unit = 1 meter

appreciate both your replies ! i ' m matching a still photo with local length . there ' s no dop / pop involved . is it safe to say i will not encounter any lighting / texturing problems if i use the default of 1 unit = 1 metre ? eitht .

rob , if you are willing to answer another question… all along i de - gamma by setting 0 . 455 gamma to my texture images in photoshop , is this the proper way or do one need other editing softwares to perform this task ? thanks in advance ! eitht .

i think the best you can do is convert your files to rat files and you can specify gamma of the texture while converting it , therefore you will have correct linear rat files you can directly use in all shaders , so no need for other software other thing you can do instead of converting is append power vop after each srgb texture in shader and set it to 2 . 2 which has the same effect as setting gamma to 0 . 45 ( rat files might be better though ) and of course don ' t forget to have linear color swatches as well , but this is handled automatically if you have edit / color settings / color correction set to 2 . 2 and checked everything

i strip out the gamma in the shader . ive found it will do 99 % of the time rob

tamte of course don ' t forget to have linear color swatches as well , but this is handled automatically if you have edit / color settings / color correction set to 2 . 2 and checked everything you referring to the color swatches in houdini ? by default , color correction / gamma was set to 1 . 0 and that makes it non - linear ? trying to wrap my head around the whole lwf , here ' s a screen - cap of what i did to the de - gamma . does the renders look like they were done correctly ? this is what i would work in the future , 1 ) de - gamma textures 2 ) render stuff out with linear color space in my mantra rop 3 ) render out my final composite with srgb color space in nuke anybody see a problem or am i on the right track now ? apologize for being long - winded ! eitht .

i assume the color settings and swatches greatly affects how the virtual lights behave too huh ? : ? eitht .

they don ' t change rendering behaviour at all , it actually doesn ' t matter how you set that setting , mantra will still compute the same result given the same input values it just changes how you see the values , so setting all to 2 . 2 gets rid of monitor gamma correction so you see directly linear values and therefore set them correctly for mantra , which can give you much realistic result compared to feeding mantra with false values and expect correct result . but it ' s all the same principle , just search for linear workflow on the internet , plenty of info there , it ' s not specific to houdini btw , saving an image from mplay which has correction 2 . 2 doesn ' t automatically bake that correction into the files ( there is an other option for gamma when you chose to save the frame ) so you probably saved images ( in your updated post ) without baking the gamma in , because neither of them looks correct , but if you apply gamma 2 . 2 on the second one , it may be correct .

i am understanding this much better now ! baking the gamma in is this checkbox in the screen - cap ? that ' s what i did when i saved both of the images above . i was told simply typing 2 . 2 into mplay doesn ' t bake it but setting this when saving out images bakes it . eitht .

it just changes how you see the values , so setting all to 2 . 2 gets rid of monitor gamma correction so you see directly linear values and therefore set them correctly for mantra , which can give you much realistic result compared to feeding mantra with false values and expect correct result . i leave all that at default and strip the gamma from textures in the shader refer to my site ( urltoken [ circusmonkey . com . au ] . i then render and in the mplay display and set my gamma to 2 . 2 . what i see in mplay on my monitor it whats important and as long as there ' s lots of range . all my renders are linear and then in comp when you output your image you can set the gamma to 2 . 2 if you wish . as a standard though i always deliver linear for the render out of nuke . the next question i swear we will get is why are lights in houdini set using intensity and not stops ! rob

i cant thank you guys enough for the explanations given so far ! and rob ' s prediction was spot on… i started a topic related to lights . : shock : will visit your webby , cheers ! eitht .

with the screen shot below , am i understanding houdini grids , is each grid 1 meter ? if i wanted to model something that is 0 . 28194 width in meters how can , this may be really simple question create a cube which is of that width ? also when creating large bodies of water as a example how do you any of you get the measurements of a body of a water ?

houdini is life cereal , once you had a bowl you can ' t stop .

looks like no one’s replied in a while . to start the conversation again , simply ask a new question .

after that , i experiences some crash , then webkit web inspector got broken .

also , delete key doesn ' t make " back " . is it normal ?

i did try " reset safari " but it didn ' t help . disabling extension and plugins also didn ' t help .

the webkit web inspector is completely broken for me , while the new web inspector is a real pain to use . i feel like it cut my productivity in half . for now i guess i have to move to chrome .

i really dislike the new web inspector . i submitted feedback here asking the at least give us the old one back as an option : urltoken

i noticed the exact same thing . i think it ' s a bug for sure . if anyone has found a workaround please share . the other issue i am having is using the new web inspector in investigate the dom tree . i use the " inspect element " option frequently in debugging sites , but now the view seems to have word wrapping on the inspector window which makes reading the code almost impossible if you are inspecting an element that is several level deep in on the dom . does anyone know if word wrap can be turned off in this view ?

i know you can click on the dom tree element and switch to ' source code ' but them you lose the element inspector view .

i installed the nightly webkit build and was able to use the webkit inspector , but i can ' t figure out how to get files open in new scripts tab unless i happen to hit an exception or something . clicking on line numbers in the resources tab no longer sets a breakpoint . how do you set a breakpoint now ?

apple , if you ' re listening , this is the sound of your developers fleeing the platform . this is not hyperbole , this is reality - - safari is no longer useful to develop for the open - standard web that you ' ve pushed so very hard for .

agreed as well . i had recently moved to safari from chrome and was really appreciating the polish it brought to everything , but a non - functional web inspector is a non - starter for a web developer like myself .

i gave it an honest effort , also for about a week , but found it made 100 % of tasks 1000 % slower and more difficult . just having it open effectively broke any web page with heavy js use .

i sent apple feedback with a full list of problems from my perspective . i ' d encourage others to do the same .

such a shame . . . chrome feels primitive in so many areas of ui integration .

i give up . safari ' s web inspector is worthless for examining network requests . i ' ve been using safari , chrome and ff , with safari as my main browser , but no more bcause i cannot do the work i need to .

this site contains user submitted content , comments and opinions and is for informational purposes only . apple may provide or recommend responses as a possible solution based on the information provided ; every potential issue may involve several factors not detailed in the conversations captured in an electronic forum and apple can therefore provide no guarantee as to the efficacy of any proposed solutions on the community forums . apple disclaims any and all liability for the acts , omissions and conduct of any third parties in connection with or related to your use of the site . all postings and use of the content on this site are subject to the apple support communities terms of use .

strobing , highlighting , bathing in the dust of a thousand angelic fairies — call it what you want , this bright and dewy makeup trend has taken over the beauty world . but there are a handful of highlighter mistakes you ' re making that could be the reason you think this trend isn ' t working for you . don ' t worry , i fancy myself somewhat of a highlighter expert and can teach you exactly how to correct those mistakes .

the highlighting or strobing trend can make us look like glowy , gorgeous vampires in the sun — if we do it right . correctly done , a highlight on the face lifts , brightens , and improves the overall look of your skin and makeup . it ' s a great way to play up the features you love , while making your natural skin look more luminous and healthy .

if the trend isn ' t working for you , you may have an application or formulation issue . a great highlight is made to look dewy , not oily . it grabs attention , instead of spotlighting something you ' d rather hide , like scar or uneven skin texture . but if you ' re having trouble achieving a perfect sparkling highlight that looks great on you , you may be making some serious highlighter mistakes .

instead of looking like a golden , mythical greek goddess you wanted to , you came out looking like a grease ball . no worries . to achieve a more " glowing from within " look that doesn ' t play up natural oily skin , apply your highlighter after your foundation but before your blush . doing this will minimize the shine while still giving you an illuminated appearance .

beaming like a lighthouse ? if you ' re not into the extreme strobe look or just want to tone things down for a more daytime appropriate style , you can blend a drop of liquid highlight into your foundation . this is a great alternative if you prefer a " less is more " look , or aren ' t into packing on the products .

light is great , but sparkles are best left for the ' 90s ( unless that ' s your jam ! ) . if your highlight looks like you just took a sparkly body roller to the face , you may be using a bad formulation . drugstore dupes for higher - end products can work , but sometimes there ' s a reason they come at a lower price point : the formulation is chalky , patchy , or sparkly . if this sounds like you , begin the hunt for a creamier powder . my favorite is , of course , jaclyn hill ' s champagne pop . it ' s extremely creamy , so it blends seamlessly into my skin instead of sitting on top of it like a bad frosting .

face looking a bit larger than usual ? yes , strobing can actually make your face look wider if you are not highlighting in the correct spot . it ' s important to highlight the cheeks and above , never sweeping highlight below the cheekbone . remember : lifting up ( literally , anything like bronzer , eyeshadow , blush , or highlight ) will help the whole face look lifted , tighter , and younger . dragging product down lower than it needs to go on your face will only make you look more tired .

you tried the highlight trend , only to find every pore of your face visible ? you may be highlighting in the wrong area for you . i love the highlighted look , but i often get uneven texture on the tops of my cheeks and have to skip highlighting in that area . instead , i highlight my cupid ' s bow , nose , chin , and above the brow bone . if there ' s a particular area you have trouble in ( let ' s say , you hate the bridge of your nose ) then definitely skip highlighting that area . just because you can , doesn ' t mean you have to . find the highlight area that looks best on you and forget the rest !

looking more casper and less cara delevingne ? you may be using a highlight shade that is too light for your skin tone . there are all kinds of highlighter shades on the market , some with peachy , pinky , bronze , or white undertones . if you are pale skinned , pinks look gorgeous on you . if you are medium , peachy highlighters are beautiful . if you have dark skin , you should rock peach to bronze highlights . as long as the powder or cream is two to three shades lighter than your foundation , you are good to go .

if you want to watch a highlight pro in action , check out jaclyn hill ' s makeup tutorial for how to properly use a highlighter cream .

do you know how many calls agent number 29 can handle in a given hour ? is this the only metric you need to measure ? in the era of the call center on demand , what metrics are you using to determine success ? if it’s simply based on the number of calls , you may be headed for disaster .

a recent metrics piece highlighted the challenge of looking at success with just the number of calls mentality . the example given had much to do with “i love lucy” and a certain candy factory assembly line episode . whether you’re old enough to remember the episode or not ( i am only old enough to remember the “nick at night” version , thank you very much ) the point is simple – they received too little training to maintain the expected level of activity .

the first few minutes on the chocolate line went fine , but as soon as the assembly line needed to increase in speed , there was no way our beloved characters could keep up . is this really the approach agents should take in the call center on demand ? if the goal is simply to complete a set number of calls within a set amount of time , will you truly achieve goals that mean anything ?

in the lasagna example , i’ve trained my daughter to do one lasagna well and then expected her to apply it across too many in less time . i didn’t show her how to develop an assembly line to putting the lasagnas together or give her adequate time so that quality was maintained . the timing pressure also is sure to lead to a bigger mess in the kitchen and a stressed out teenager .

the call center on demand requires a different approach as well . while you do want to have guidelines for the number of calls you would like agents to complete , isn’t the outcome of the call more important ? if they reach 20 prospects in a given hour and none of them turn into sales , were these 20 quality interactions ? if the same agent could instead reach five prospects in the hour and turn three of them into sales and two of them into potential leads to contact later , the outcome is so much better .

this is why it’s important to get away from the calls per hour mentality . while the “quality over quantity” mantra may seem tired , it’s still a valuable rule in the call center on demand . go for the metrics that drive the outcomes you need and not just activity or there soon won’t be any activity to drive .

html public " - / / w3c / / dtd xhtml 1 . 0 transitional / / en " " urltoken "

if this is your first visit , be sure to check out the faq by clicking the link above . you may have to register before you can post : click the register link above to proceed . to start viewing messages , select the forum that you want to visit from the selection below .

for quite some time , i ' ve wanted to work on a new mandolin design which has the features desired by f - style players , but with post - victorian style , and the complexity allowed by modern tooling .

a fancy " strap holder " which was sleek and modern but maintained f body balance .

" 3 - d binding " which highlighted the form of the instrument , protected the edges and didn ' t require bending plastic .

a headstock which was attractive , had f - style mass but was sleek and didn ' t get complicated with scroll work .

comfortable tuning and easy neck adjustment . ( the prototype has alessi tuners and a two - way truss rod . )

tone and playability in the " modern - bluegrass " mode with a powerful chop and clear , even response across the neck .

my cohort , randy torno , suggested that i should dribble out a few detail pictures to get started . that ' s just cruel isn ' t it ?

steve sorensen sorensen mandolin & guitar co . urltoken " on the bench today " updates on facebook

he swings . . . . . . . he hits . . . . . . . it ' s gone ! ! ! . . . . . . . . . . what a great looking instrument steve ! ! ! ! ! love it when folks think outside the traditional f - 5 box . . . . . . . . . . can you talk a little about how you did the binding ? ? ? it ' s really nice the way it flares out at the points and such . . . . . . . . . . really good job . . . . . . . . . jim urltoken

i love it ! ! beautiful , beautiful work steve . i also love the binding flare at the points . the inlay is great as is the tailpiece design . how about a picture of the entire instrument and some of the back .

steve , need a drooling emoticon . that is effin awesome ! ! need to see how college financial aid works out , but i may be contacting you in the next few weeks . . . very cool design , indeed !

yeah . . . pretty much have to have one of those . . .

there are three kinds of people : those of us that are good at math and those that are not .

steve davis i should really be practicing instead of sitting in front of the computer .

music speaks to us all . and to each of us , she speaks with a different voice . j bovier a5 tradition

that ' s drop dead gorgeous right there steve . that headstock is the stuff of headstock posters . the body and head stock binding is very cool looking and is visually reinforced by the bound pickguard . given the short grain in some areas of the binding , you must have selected a tough as well as beautiful species of wood . can ' t wait to see vids of this one ! scott

steve , thank you for sharing these . . . you nailed it ! i love it , i would love to see some full photos like larry mentioned , and an audio clip . . . i seriously want one of these . i assume you ' ll have additional info on these soon , but i ' ll connect via your website to email / discuss lead times , availability , etc . beautiful , sophisticated . . . . good stuff . . . i ' m sold on the looks and really look forward to hearing one ! jason urltoken

steve , you are out of control - - in the very best of ways . that design is crazy cool . i was just talking to my wife about your mandolins yesterday , showing her photos and describing the models . i noted that if someone gave me a certificate for any sorensen mandolin of my choice , i just don ' t know what i ' d do . you have now made this even more difficult ! i need to visit your shop someday and play them all . beautiful work , as usual . kudos .

i screwed some hooks into our cedar fence to hang a ladder , but yeah , your skills are pretty good , too , i suppose .

cool design , outside the box but still has all the features of an f style .

fresh design ! i ' m looking forward to having you join us in the lutheirs pavilion at the big cba father ' s day bluegrass festival in grass valley this june . instruments like this should stir up the folks .

wow ! ! ! - that ' s ' radical ' for sure - amazingly so . lovely design , wonderful craftsmanship & an absolute show stopper . terrific work steve , ivan

weber f - 5 ' fern ' . lebeda f - 5 " special " . stelling bellflower banjo tokai - ' tele - alike ' . ellis deluxe " a " style .

" have i not commanded you ? be strong and courageous . do not be afraid ; do not be discouraged , for the lord your god will be with you wherever you go . " ~ joshua 1 : 9

back neck and sides are sugar maple . one - piece back ; two - piece bookmatched neck .

top is a one - piece sitka spruce with amazing silking . " parallel " tone bars .

this instrument is a prototype , so the real goal is for the build and the resulting instrument to help refine the process and components for future builds . based on how this came together , i ' m looking forward to doing it again !

players in the future ! hopefully i ' ll be able to snag some good video / sound .

as michael lewis mentioned , we do have a table at grass valley in june ; randy torno will be teaching a jam class at huck finn jubilee ; we ' ll also be at ibma in september .

for a geometric object to participate in a physics simulation , it must have the massfx rigid body modifier applied . ( alternatively , use the mcloth modifier . ) the easiest way to convert an object to a rigid body is by selecting the object and then choosing the appropriate rigid body type from the flyout on the massfx toolbar .

as indicated by the path annotations at the start of this topic , you can apply the rigid body modifier to objects in any of several different ways . when applying the modifier to more than one object at a time , using the animation menu or massfx toolbar method results in a separate modifier per object . however , choosing the modifier from the modifier list results in an instanced modifier on each object . to edit the instanced modifier , you can select any object to which it is applied , and the changes will affect all instances of the modifier .

with non - instanced modifiers , the modify panel rollouts for the rigid body modifier are available for only one object at a time ; if multiple rigid bodies are selected , the rollouts do not appear . however , you can edit multiple selected rigid bodies on the

of the massfx tools dialog . most of the editor controls are the same as those on the modify panel .

the modifier stack for rigid bodies provides access to visualization of a number of settings that affect the simulation . when a sub - object level is active , you can change how the simulation begins and proceeds by transforming the respective gizmo .

this level shows a visualization of the axis and direction of the initial spin for the rigid body . use the rotate tool to change the axis .

this level shows a visualization of the location of the center of mass for the rigid body . use the move tool to change the location .

this level lets you adjust the position and rotation of a physical shape for the rigid body . highlight the physical shape to transform in the list on the physical shapes rollout ; the physical shape will draw in white wireframe in the viewports . use the move and rotate tools to adjust the physical shape ' s relative placement with respect to the rigid body .

the simulation type for all selected rigid bodies . the available choices are dynamic , kinematic , and static . for details , see

when on , massfx converts the selected kinematic body to a dynamic one at the specified frame . available only when rigid body type is set to kinematic .

this means you can animate an object using standard methods and set rigid body type to kinematic so it performs as animated until the designated frame . at that point it becomes a dynamic object and is then subject to the full massfx simulation forces .

for example , to re - create a baseball game , you might animate the ball leaving the pitcher ' s hand and flying toward the bat . then , using until frame , when the bat strikes the ball , massfx would take over and accurately simulate the action of the batter hitting a home run ( or fouling out ) .

a rigid body need not be animated to take advantage of this feature . for example , you might want to suspend several stationary bodies and then drop them at different times . to do so , simply set them all to kinematic and turn on until frame , then select each one in turn and specify the frame at which it should start being subject to gravity and / or other forces .

converts the simulated motion of the rigid body to standard animation keyframes for rendering . applies only to dynamic rigid bodies .

. this means that it will not move until struck by a non - sleeping rigid body . for example , to simulate a domino rally , start all of the dominos except the first in sleep mode .

when on ( the default ) , the rigid body collides with other rigid bodies in the scene .

the physical material properties control the way the rigid body interacts with other elements in the simulation : its mass , friction , bounciness , and so on . you can set the material properties one at a time , or use a preset to simulate real - world substances such as cardboard or rubber .

use the drop - down list to choose the physical shape of the rigid body for which you are changing the material parameters . by default , all physical shapes use the common material setting labeled " ( object ) " . only physical shapes whose

choose a preset from the list to specify all physical material properties . ( the mass of the rigid body is recalculated based on the value of the density and the volume of the object . ) when a preset is chosen the settings are not editable , but when preset is set to ( none ) you can edit the values freely .

to use the settings from a different rigid body in the scene , click and then select a rigid body in the scene .

at the bottom of the list are commands to load and save a preset as a file and to create a new preset .

( grams per cubic centimeter ) . this is one thousandth of the equivalent measurement in si units : kg / m

. changing this value automatically calculates the correct mass for the object , based on its volume .

the weight of this rigid body , measured in kg ( kilograms ) . changing this value automatically updates the density of the object , based on its volume .

the degree of difficulty for two rigid bodies to start sliding against one another . a value of 0 . 0 indicates no friction ( more slippery than teflon ) ; a value of 1 . 0 indicates full friction ( rubber cement on sandpaper ) .

the effective static friction between two rigid bodies is the product of their static friction values . if one rigid body has a static friction of 0 . 0 , it doesn ' t matter how what the value of the other is . ( everything slides on wet ice ; even sandpaper . ) once the two objects start sliding , the dynamic friction ( see following ) applies instead .

the degree of difficulty for two rigid bodies to keep sliding against one another . technically , this parameter is called the " coefficient of kinematic friction . " a value of 0 . 0 indicates no friction ( more slippery than teflon ) ; a value of 1 . 0 indicates full friction ( rubber cement on sandpaper ) .

in the real world , this value should be less than the coefficient of static friction . ( it ' s harder to start pushing a couch across the floor than it is to keep it moving . ) as with static friction , the effective value between two rigid bodies is the product of their respective values .

how easily and high an object bounces when it hits another rigid body . technically , this parameter is called the " coefficient of restitution . " a value of 0 . 0 indicates no bounce ( a lump of peanut butter dropped on carpet ) ; a value of 1 . 0 indicates that the object will bounce off just about as hard as it hit . the effective bounciness between two rigid bodies is the product of their bounciness values . a super - bouncy rubber ball landing on peanut butter will not recover .

use this rollout to edit the physical shapes assigned to an object in the simulation . you can use the controls to add and remove physical shapes , change the shape type , copy physical shapes between objects , and more . when you run the simulation , massfx uses all assigned physical shapes to represent the object ' s physical presence . for more information , see rigid body overview .

shows all the physical shapes that comprise the rigid body . highlight a physical shape in the list to rename it , delete it , copy and paste it , change its mesh parameters or affect its transform via the

applies a new physical shape to the rigid body . by default , the new shape is the convex type and covers the entire graphical mesh , the same was when you first apply the massfx rigid body modifier to an object . after you add a shape , it ' s highlighted in the list so you can change the shape type , properties , and so on .

change the name for the highlighted physical shape . this name is just for your own use to easily identify multiple physical shapes .

delete the highlighted physical shape from the rigid body . ( the last remaining physical shape for a rigid body cannot be deleted . )

copy the highlighted physical shape to the clipboard for subsequent pasting ( see following ) . the physical shape ' s parameters and local transform are copied along with the mesh .

paste a previously copied physical shape ( see preceding ) onto the current rigid body .

the new physical shape is not an instance ; any changes you make to the originally copied physical shape do not affect the new physical shape after pasting .

flips the shape geometry around the specified axis ( see mirror shape settings , following ) .

opens a dialog for setting the axis along which the shape is mirrored , and whether to use the local axis or the world axis .

adapts the highlighted shape in the list to the current state of the graphical mesh . use this to re - fit the physical shape to the graphical mesh after editing either . examples might involve transforming sub - objects or scaling the object .

applied to the highlighted item in the modify shapes list . the available types are sphere , box , capsule , convex , concave , original , and custom . sphere , box , and custom are massfx primitives and simulate more quickly than other hulls . for best performance , use the simplest type you can get away with .

the contents of this rollout vary , depending on the shape type setting . for descriptions of the parameters for each type , see massfx physical shape types .

changing the shape type generates a new shape of the chosen type sized to fit around the graphical mesh . the options for the shape , which depend on the chosen shape type , are available on the physical mesh parameters rollout ( see following ) .

for example , take the teapot primitive and apply the rigid body modifier with generate shape per element on . this creates four physical - shape elements by default , of which the first is the body of the teapot : element 1 . if , with element 1 highlighted in the shapes list , you choose element 2 ( the handle ) from the shape element list , massfx reshapes the teapot body physical shape to the handle . or if you choose all elements , element 1 takes on the shape and size of the entire teapot mesh . if you then change the shape type setting , say from convex to box , the result is a physical shape of that type that fits around the active shape element item .

clicking this button creates a new editable mesh object in the scene from the highlighted physical shape and sets the shape type to custom . you can use standard mesh - editing tools to adjust the mesh , then update the physical shape from it . for more information , see

. however , you might be working with a complex rigid body that comprises many physical shapes , where you want to use different settings for certain physical shapes . in this case , turn on override physical material . all properties in this section work as described for the physical material rollout , but apply only to the selected physical mesh .

when on , renders the physical shapes as shaded , solid objects in shaded viewports , rather than as wireframes . also turns on the

use the forces rollout to control gravity and apply force space warps to the rigid body .

use world gravity when off , the rigid body uses only forces applied here and ignores the global gravity setup . when on , the rigid body uses the global gravity setup . scene forces applied lists force space warps in the scene that affect this object in the simulation . use add to apply a space warp to the object . to prevent a space warp from affecting the object , highlight it in the list and then click remove . add applies a force space warp in the scene to the object in the simulation . after adding the space warp to the scene , click add and then click the space warp in the viewport . remove prevents an applied space warp from affecting the object . first highlight it in the list , then click remove .

set the numeric value to the desired number of times the solver enforces collisions and constraints . higher values might be necessary when the simulation uses many constraints , or the tolerance for joint errors is very low . a value higher than 30 is generally unnecessary .

for a concave static rigid body , turn this on to ensure that dynamic objects in the simulation collide with its back faces .

for example , take a box primitive , convert it to editable poly format , remove a side , and then make it a static rigid body with the original shape type . if you then place a dynamic object inside the box , turn on enable backface collision for the box to keep the object from falling through the sides .

use these settings to determine the surrounding volume within which massfx detects collisions between bodies in the simulation .

an excessively high value can cause objects to interpenetrate visibly . setting this value too low can cause jittering because objects alternate between interpenetrating one frame and being forcibly separated the next .

the best value depends upon variety of factors , including the size of objects in the scene , the proximity of the camera to possible interpenetrations , the settings for gravity acceleration and solver iterations , the inflation amount of the physical shapes , and the frame rate of the simulation .

the distance that resting bodies are allowed to overlap . this setting can come into play when using

changing the contact distance value automatically changes the rest depth value to the new contact distance value plus the difference between the two . for example , say contact distance is 10 . 0 and rest depth is 8 . 0 ( difference = –2 . 0 ) . if you then change contact distance to 6 . 5 , rest depth automatically changes to 4 . 5 ( 6 . 5 + ( –2 . 0 ) ) . however , changing the rest depth value does not affect contact distance .

this setting applies only to rigid bodies that start out kinematic ( typically these are already animated ) and then switch to dynamic at the frame specified by the until frame setting on the rigid body properties rollout . normally , the initial velocity and initial spin of such bodies are calculated based on the animation for the last frame before they become dynamic . when this option is set to absolute , the values of initial velocity and initial spin ( see following ) are substituted for the animation - based values . when set to relative , the specified values are added to the values calculated from the animation .

the starting direction and speed ( in units per second ) for the rigid body when it becomes dynamic . the xyz parameters are maintained as a normalized vector , which can be difficult to edit or picture . to visualize the initial velocity direction and optionally change it with the

the starting axis and speed ( in degrees per second ) for the rigid body ' s rotation when it becomes dynamic . the xyz parameters are maintained as a normalized vector , which can be difficult to edit or picture . to visualize the initial spin axis and optionally change it with the

applies to animated , kinematic rigid bodies . determines the motion values ( see preceding ) for the animated object at the current frame and then sets the initial velocity and initial spin fields to those values .

use this function to apply initial motion values from a point in the animation of the kinematic body other than those at the frame at which it becomes dynamic .

the point around which a rigid body rotates unless constrained in some way . to visualize and adjust this point graphically for the rigid body , use the center of mass sub - object level .

calculate from meshes automatically determines an appropriate center of mass for the rigid body based on its geometry .

lets you set a distance from the object ' s pivot on the x , y , and z axes to use as the center of mass .

move pivot to com relocates the object ' s pivot at the center of mass specified by the local offset xyz values . available only when local offset is active .

damping slows down the rigid bodies . typical uses include reducing oscillations in a simulation or causing an object to appear to be traveling through a dense medium .

select ragdoll selects the ragdoll to which the rigid body belongs . available only when the rigid body is part of a ragdoll object .

massfx physical shape types this topic covers the parameters rollouts and settings for the various physical shape types in massfx .

connect , consult with , and hire trusted industry experts on the autodesk services marketplace .

except where otherwise noted , work provided on autodesk knowledge network is licensed under a creative commons attribution - noncommercial - sharealike 3 . 0 unported license . please see the autodesk creative commons faq for more information .


biogen , inc. ( previously known as biogen idec ) is an american multinational biotechnology company based in cambridge , massachusetts , specializing in the discovery , development , and delivery of therapies for the treatment of neurodegenerative , hematologic , and autoimmune diseases to patients worldwide .

biogen

biogen <EOT> idec completes a merger with biogen , inc . , creating biogen idec inc .

principal subsidiaries : biogen idec ma inc . ; biogen idec u . s . corporation ; biogen idec u . s . limited partnership ; biogen idec holding i inc . ; biogen holding ii inc . ; the biogen idec foundation inc . ; biogen idec ( rtp ) realty l . l . c . ; biogen idec realty corporation ; biogen idec realty limited partnership ; biogen idec u . s . west corporation ; biogen idec u . s . pacific corporation ; biogen idec nobel research center , l . l . c . ; biogen idec trade services building , l . l . c . ; biogen idec manufacturing operations , l . l . c . ; biogen idec canada inc . ; biogen idec austria gmbh ; biogen idec belgium s . a . / n . v . ; biogen idec b . v . ( netherlands ) ; biogen idec international b . v . ( netherlands ) ; biogen idec ( denmark ) a / s ; biogen idec ( denmark ) manufacturing aps ; biogen idec finland oy ; biogen idec ( france ) ; biogen idec gmbh ( germany ) ; biogen iberia sl ( spain ) ; biogen idec limited ( u . k . ) ; biogen idec norway as ; biogen idec portugal ; biogen idec sweden ab ; biogen idec ( switzerland ) gmbh ; biogen dompe s . r . l . ( italy ) ; biogen dompe ag ( switzerland ) ; biogen idec australia pty . ltd . ; biogen idec japan ltd . ; idec seiyaku ( japan ) ; biogen idec ( bermuda ) investments limited ; biogen idec ( bermuda ) investments ii limited ; biotech manufacturing c . v . ( netherlands ) .

you are now leaving biogen australia’s corporate website to a third party site that manages links to product information and consumer medicine information , on biogen’s behalf .

the acquisition supports biogen ' s goal to develop multiple sclerosis products , biogen said , news sources report . financial terms of the agreement were not disclosed .

these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc . ’s ( “biogen” ) website . find out more .

have similar therapies in development that could eat into biogen ' s market share . will biogen sew up the hemophilia b market only to watch it quickly unravel ?

learn how biogen , sobi and the wfh are impacting hemophilia around the globe .

these terms and conditions of use describe the terms and conditions applicable to your use of biogen idec ltd . ’s ( “biogen” ) website . find out more .

biogen will spin off its hemophilia drug business as a separate company early next year .

the study is funded by biogen . dr sandrock is an employee of biogen . disclosures for the coauthors are in the paper . dr hendrix has disclosed no relevant financial relationships .

as a wellness company deeply committed to helping south africans become more active and healthy , biogen have forged a partnership with avianto trails to form the biogen sports park @ avianto .

idec to merge with biogen in $ 6 . 8 billion deal - the new york times

at biogen , our mission is clear : we are pioneers in neuroscience . biogen discovers , develops , and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases .

skyland analytics appoints james c . mullen , former biogen and patheon ceo , to advisory board

our target price for biogen ( consolidated ) is $ 338 . 50 per share . this reflects biogen’s robust ms drug portfolio , impending spin - off and initiatives to diversify into new disease areas . this suggests about 20 % upside from biogen’s current stock price of $ 283 . our fair value for bioverativ is $ 6 . 1 billion ( or $ 27 . 75 per biogen share ) . our valuation for core biogen ( biogen without bioverativ ) is $ 61 billion ( or $ 278 . 25 per biogen share ) . the record date for the spin - off is january 17 th . the spin ratio if 1 : 2 , implying each biogen shareholder will receive 1 share of bioverativ shares for every 2 shares of biib .

tennille discusses her role in supporting patients living with devastating neurological diseases who are taking biogen medicines .

biogen is committed to working with advocacy and patient organizations as they serve the communities they represent .

official twitter channel for biogen . focused on cutting - edge science and medicine . community guidelines :

karol discusses how biogen is using human genetics to identify targets for new drugs . karol’s work in alzheimer’s disease is an example of how biogen is working to develop therapies that could address unmet need .

in all , the restructuring process will cost biogen up to $ 95 million in the fourth quarter .

you are now leaving biogen’s corporate website . we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

biogen and eisai announced positive topline results from their phase ii clinical trial of ban2401 in alzheimer’s disease .

biogen signed an exclusive option deal with tokyo - based tms for tms - 007 and backup compounds .

you are now leaving biogen canada’s website . we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

adam feneley , managing director , biogen , commented : “the acquisition is another exciting milestone in biogen’s history which further enhances the company’s reputation as the number one food waste to renewable energy company in the uk . the investment is excellent news for biogen and marks the next stage of growth for the business . ”

under the terms of the deal , each biogen share will be exchanged for 1 . 15 shares of idec . based on friday ' s closing prices , there was no premium being paid to biogen shareholders .

swedish partners just how much biogen idec stands to keep from alprolix sales is still an unknown . when biogen acquired the therapy , it also inherited a complicated collaboration agreement with swedish orphan biovitrum , or sobi .

you are now leaving biogen australia’s corporate website . we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

but with all of this good news , biogen stock is trading at nearly the same level as it did at the beginning of 2017 . do biogen shareholders have something to worry about ? i think so .

' ' where we were going with biogen was to build things that idec already had and where idec was going was to build things that biogen already had , ' ' mr . mullen said in an interview .

nonetheless , biogen investors in particular will want to keep a close eye on this market and its potential .

biogen develops , manufactures and markets innovative therapies for patients living with serious neurological , autoimmune and hematologic disorders .

at biogen , we are dedicated to making an impact on local communities , scientific education and the environment .

biogen develops , manufactures and markets innovative therapies for patients living with serious neurological , autoimmune and rare diseases .

you are now leaving biogen international ' s website . we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

biogen shares rose $ 24 . 31 , or 9 . 4 percent , to $ 284 . 18 .

you are now leaving biogen idec ltd ' s website . we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

biogen also discontinued a number of programs , including the phase 3 program for tecfidera , a multiple sclerosis drug .

biogen ' s alprolix is now the most convenient hemophilia b treatment available , but competition is on the way .

at biogen , we are committed to improving the lives of patients living with serious illnesses and pursuing new treatments .

biogen idec has moved to beef up its pipeline by acquiring syntonix pharmaceuticals for $ 40 million down and up to $ 80 million in milestone payments . biogen idec says it will maintain syntonix ' s 25 , 000 - square - foot facility in waltham , ma . biogen gains a lead product for hemophilia b and technology for developing inhalable treatments .

) - - may 31 , 2006 - - biogen idec ( nasdaq : biib ) and fumapharm ag , a privately held pharmaceutical company , today announced that they have signed a definitive agreement for the acquisition of fumapharm by biogen idec .

at biogen , we develop , market and manufacture therapies for people living with serious neurological , autoimmune and rare diseases .

find biogen’s current and historical stock information . view our upcoming events and latest webcasts . find financial statements and reports .

idec shareholders will own 50 . 5 percent of the combined company , which will be based in biogen ' s hometown , cambridge . james c . mullen , chairman and chief executive of biogen , will be chief executive of biogen idec , while dr . rastetter of idec will be executive chairman . the board will be split evenly between the two companies .

sobi has the option to pay for final development and commercialization activities in europe and nearby regions , then pay a double - digit royalty to biogen on those sales . sobi would also pay biogen for a share of past development costs in the region . in return , sobi would receive double - digit royalties from biogen on sales outside of sobi ' s territory .

on biogen ' s annual day of service , our employees give back to the communities in which we live and work .

scientific discovery is our core . at biogen , we relentlessly pursue new therapies for diseases with few or no treatment options .

stocks to watch : boeing , apple , u . s . steel , mcdonald’s , microsemi , nordstrom , gap , biogen

anaerobic digestion company , biogen , has been purchased for an undisclosed sum from joint venture shareholders bedfordia group and kier group .

biogen has a great thing going with spinraza , but there are big questions for its multiple sclerosis franchise and pipeline prospects .

at biogen , our mission is clear : we are pioneers in neuroscience . since our founding in 1978 as one of the world’s first global biotechnology companies , biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases .

biogen contributes to the communities where we live . we are committed to our employees , diversity and inclusion , and environmental sustainability .

krasner , jeffrey , " biogen , idec complete merger , " boston globe , november 13 , 2003 , p . b3 .

third party sites biogen assumes no responsibility nor does it control , endorse or guarantee any aspect of your use of any third party sites with the exception that the third party site posts copies of the approved product information and consumer medicine information for biogen products .

at biogen , we work with healthcare professionals to ensure the therapies we create can reach those that need them . read more .

to learn more about biogen ' s executive leadership based in cambridge , ma , usa , click here for our corporate website .

one factor that could change biogen ' s valuation are the results , expected this summer , of a late - stage clinical trial for its experimental drug antegren , for crohn ' s disease , a bowel inflammation . antegren could be biogen ' s next product .

third party sites biogen assumes no responsibility nor does it control , endorse or guarantee any aspect of your use of any third party sites . additionally , the presence of this link does not imply the third party site ' s endorsement of biogen or this website .

biogen is expecting data this year on a closely watched medicine known as anti - lingo that could become the first to restore nerve damage caused by multiple sclerosis . based on the phase ii data , biogen will decide whether to proceed to a pivotal registration trial .

explore the latest biogen news and information including all current and archived press releases . you can also sign up to receive email alerts .

at biogen , we discover , develop , manufacture and commercialize innovative therapies for people living with serious neurological , autoimmune and rare diseases .

biogen is one of the world’s leading biotechnology companies , with a focus on developing therapies for serious neurological , autoimmune and rare diseases .

turnaround trio : marketing boss tony kingsley , research chief doug williams , and ceo george scangos have made biogen idec a favorite of investors .

the biotech sector has been slammed this year on concerns about price gouging . biogen shares are down 21 % year - to - date .

biogen announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on thursday , june 28 , 2018 .

gilmore o’neill , formerly biogen’s senior vice president , late - stage clinical development , jumped ship and will be sarepta therapeutics’ chief medical officer .

biogen was established in 2005 by bedfordia chairman , john ibbett . ancala bioenergy ltd is an infrastructure investment vehicle managed by ancala partners llp .

biogen respects your skills and appreciates your contributions . work environment and technical tools available are excellent . it department is responsive to all requests .

the companies do have somewhat complementary products . idec has specialized in cancer and was moving into autoimmune diseases . biogen started with drugs for autoimmune diseases and was moving into cancer . indeed , merger talks began earlier this year after biogen licensed some of its cancer drug candidates to idec .

biogen’s introducing investors to its hemophilia spinoff - - and the company may be hoping it’ll take some attention away from recent buyout buzz , too .

according to a press release , biogen expects to complete the majority of the layoffs by the end of 2015 , and is notifying affected employees .

the hemophilia drug franchise that biogen inc . plans to spin off as a separate company early next year has been given a name : bioverativ .

please be advised that all legitimate correspondence from a biogen employee will come from " @ urltoken " or “ @ brassring . com” email accounts .

“being at biogen has changed me as a scientist and the way i think about asking questions that could potentially make a difference for patients . ”

much like the periodic table of elements documents the building blocks of the universe around us , the biogen elements give shape to our company’s culture .

in 2016 , biogen spent $ 106 million on advertising , versus $ 108 . 6 million in 2015 and $ 92 . 9 million in 2014 .

even so , scangos said last february , they “still have no strategic alignment with the rest of what we’re doing . ” bioverativ’s cox , a longtime biogen manufacturing executive , says that biogen had to make some decisions about how to allocate its capital . some $ 1 billion or more could be needed for aducanumab’s phase 3 trials alone . though the hemophilia products are profitable , they were a small part of biogen and didn’t really “move the needle , ” he says . despite rumors biogen was shopping the business , no deal ever materialized , and the bioverativ spin - out was formally announced last may .

biogen reported encouraging results from an early - stage study of aducanumab in the fourth quarter of 2016 . it ' s possible that the experimental drug could prove successful where others haven ' t . however , there is certainly a high level of risk associated with biogen ' s alzheimer ' s disease efforts .

biogen idec creates new standards of care in oncology , neurology and immunology . as a global leader in the development , manufacturing , and commercialization of novel therapies , biogen idec transforms scientific discoveries into advances in human healthcare . for product labeling , press releases and additional information about the company , please visit urltoken .

the pharmaceutical company merger spree has produced corporate names like glaxosmithkline and astrazeneca . now the biotechnology industry is getting its own combination nameplate - - biogen idec .

cambridge , massachusetts - based biogen exercised its option to acquire additional shares of samsung bioepis , a joint venture with samsung biologics that was founded in 2012 .

global haemoglobinopathies market to reach $ 8 . 99 billion by 2022 – leading players are gamida cell , alnylam pharmaceuticals , biogen idec , genetix pharmaceuticals and more

excluding special items , such as restructuring costs , biogen earned $ 4 . 50 per share , handily beating wall street expectations of $ 4 . 08 .

bioverativ will market biogen’s two hemophilia drugs , eloctate and alprolix , both approved by the food and drug administration in 2014 , and work to develop other treatments for blood disorders . it will be led by chief executive john g . cox , who has been the biogen executive vice president for pharmaceuticals operation and technology .

“to me , it’s a rational split , ” says jonathan gertler , ceo of biotech consulting firm back bay life science advisors . biogen removed the “distraction” of a hemophilia business that the company couldn’t spend the time or resources trying to defend or bolster . “that’s not something that’s core to biogen , ” he says .

biogen acquired eloctate , which treats hemophilia a , and alprolix , which treats hemophilia b , through its $ 120 million buyout of syntonix pharmaceuticals inc . of waltham in 2007 . the two drugs had combined sales of $ 554 million last year , about 5 percent of biogen’s overall revenue of $ 10 . 8 billion .

as a leading company in the fight against multiple sclerosis , biogen is applying its expertise to help address some of most challenging and complex diseases of the brain .

we encourage you to read and evaluate terms of use , privacy , security and other similar policies of the destination site as they may differ from biogen’s standards .

john cox has served in his current position since june 2010 . he joined biogen in 2003 and has held several senior executive positions with us , including senior vice president of technical operations , senior vice president of global manufacturing , and vice president of manufacturing and general manager of biogen’s operations in research triangle park , north carolina .

biogen idec has agreed to pay convergence shareholders $ 200 million upfront . the shareholders are also eligible to receive up to $ 475 million in payments tied to milestones .

as a global leader in biomanufacturing and serving niche markets , biogen idec is well - poised to deliver on the promise of hemophilia therapies that require less frequent dosing .

scangos viewed biogen’s hemophilia business—acquired through a $ 120 million buyout of syntonix pharmaceuticals in 2007—as an outlier . at a conference last february , he said he toyed with the idea of divesting the assets when he joined biogen in 2010 . but he ultimately kept them , and the deal turned out very well for biogen : syntonix yielded two fda approved drugs known as eloctate and alprolix—regular infusions of which help hemophilia a and b patients avoid dangerous bleeds . the two drugs generated about $ 560 million in 2015 .

leadership development program associate salaries at biogen can range from $ 68 , 814 - $ 75 , 102 . this estimate is based upon 1 biogen leadership development program associate salary report ( s ) provided by employees or estimated based upon statistical methods . see all leadership development program associate salaries to learn how this stacks up in the market .

biogen idec has said it will acquire privately - held swiss drugmaker fumapharm , adding a marketed drug for psoriasis to its portfolio and boosting its pipeline of multiple sclerosis treatments .

founded in 1978 , biogen is the world’s oldest independent biotechnology company . patients worldwide benefit from its leading multiple sclerosis therapies , and the company generates nearly $ 5 billion in annual revenues . biogen has a strong late stage pipeline with the potential to launch new products for multiple sclerosis , amyotrophic lateral sclerosis ( als ) and hemophilia by 2015 .

how does a fledgling company become an industry powerhouse ? by managing itself professionally and betting on the right products . the case of biogen shows how it can be done .

won u . s . approval for ocrevus in march . although biogen originally developed the drug , roche licensed it and will keep the lion ' s share of profits .

biogen ' s hopes are pinned largely on spinraza for now . there ' s no doubt that the drug will be a big success . analysts think spinraza could reach peak annual sales of around $ 2 . 5 billion . biogen will have to pay royalties to ionis , but it will reap most of the rewards from the sma drug .

biogen forecast 2016 adjusted earnings of $ 18 . 30 to $ 18 . 60 per share and revenue of $ 11 . 1 billion to $ 11 . 3 billion .

at the time , almost nobody outside biogen and its academic collaborators believed this . the prevailing thought was that the two forms of beta interferon were essentially similar and at best biogen might get f . d . a . approval only to fight a bruising marketing war with berlex for half of a relatively small market . " wall street doubted avonex , " said jeffrey casdin , an investment banker with hambrecht & quist , who has followed biogen closely . " i don ' t think anyone counted on its working . "

for help in planning a competitive strategy , biogen turned to joseph nemec jr . , a senior vice president in booz - allen & hamilton ' s new york office , who had been a consultant to the company since 1985 , when he was brought in to conduct a complete strategic review for james l . vincent , biogen ' s chairman .

biogen , one of the largest biotechnology companies in the world , was at a crossroads in 2016 . an experimental drug for the memory - robbing scourge , alzheimer’s disease , had shown signs of promise . that meant long , expensive , and risky phase 3 trials lay ahead for biogen to see if the early signals were more than a mirage .

' ' biogen idec really becomes an incredible powerhouse , ' ' william h . rastetter , the chairman and chief executive of idec , said in a conference call with analysts .

“this acquisition supports our goal of developing innovative therapeutic options for people living with ms , " said james mullen , biogen ' s president and chief executive , in a statement .

) - - biogen idec ( nasdaq : biib ) and syntonix pharmaceuticals today announced that the companies have signed a definitive agreement for the acquisition of syntonix by biogen idec . syntonix , a privately held biopharmaceutical company focused on discovering and developing long - acting therapeutic products to improve treatment regimens for chronic diseases , has multiple pre - clinical programs in hemophilia .

from additional data or analysis , that regulatory authorities may require additional information , further studies , or may fail to approve the drug , or that the company may encounter other unexpected hurdles . for more detailed information on the risks and uncertainties associated with biogen idec ' s drug development and other activities , see the periodic reports of biogen idec inc . filed with the securities and exchange commission . biogen idec assumes no obligation to update any forward - looking statements , whether as a result of new information , future events or otherwise .

the us is biogen ' s largest market , bringing in more than 60 % of total revenues . europe follows , with germany alone representing more than 5 % of revenues .

the successful completion of the sale will mean further growth opportunities for biogen and provide an established platform for ancala’s expansion in the waste - to - energy sector , it says .

biogen achieved its success through the years on the strength of its multiple sclerosis ( ms ) drugs . however , the company ' s ms franchise appears to be losing steam .

another similarity to big pharmaceutical companies is that the big biotechnology companies themselves are looking to license products from smaller biotechnology companies to spur their growth . biogen and idec executives said they expected half the products in biogen idec ' s pipeline in 2010 would be licensed from others , and a reason for the merger was to be able to better compete for such deals .

the companies are currently evaluating experimental drug bg - 12 in a range of diseases , including multiple sclerosis and psoriasis . biogen licensed the worldwide rights to bg - 12 from the swiss company in 2003 . additionally , fumapharm sells psoriasis drug fumaderm in germany and biogen said it plans to take over the drug ' s manufacturing and marketing once the acquisition is final .

neuropathic pain is also the indication of a phase ii biogen idec compound , neublastin . as of november 20 , 2014 , biogen idec was recruiting participants for a phase ii study designed to assess the efficacy of intravenous neublastin in improving pain in painful lumbar radiculopathy participants when administered three times per week for one week , according to a posting on clinicaltrials . gov .

avonex is marketed through biogen ' s direct sales force to specialist physicians and hospitals in north america , europe , and select other countries around the globe . the company also handles global marketing efforts for tysabri . genentech handles sales and marketing duties for rituxan , while marketing duties for fampyra are split with acorda ( biogen sells the drug in europe and canada ) .

biogen’s quarterly results should help put a difficult 2015 in the rear view mirror and allow for a renewed focus on potentially important drugs the u . s . biotech company is developing .

the sweeping cuts follow months of scrutiny tied to biogen ' s ms franchise , perceived by analysts to be underperforming . the company is facing more and more competition in its home territory as new oral and injectable therapies hit the market , and a handful of r & d setbacks over the last year has intensified questions about biogen ' s strategy for future growth .

howell , donna , " idec pharmaceuticals scoops up biogen in the largest biotech merger since ' 01 , " investor ' s business daily , june 24 , 2003 , p . a1 .

bioverativ was spun - off by biogen inc . ( nasdaq : biib ) in early 2017 so it could separate its global hemophilia business into an independent , publicly traded global biotechnology company .

biogen should be able to still grow earnings , albeit slowly , with the current ms franchise and good progress for spinraza . and if the company ' s alzheimer ' s disease program is successful , that would be a game changer . biogen investors probably should be at least somewhat worried about the challenges facing the biotech . however , there ' s no need for panic .

" biogen idec is perfectly positioned to continue the development of bg - 12 because of its global commercial and regulatory experience and unsurpassed expertise in ms . we are proud of the work that fumapharm has accomplished in the last 20 years and are confident that biogen idec will continue our legacy of helping patients , " said dr . hans peter strebel , chairman and ceo of fumapharm .

small companies with large competitors must ever seek leverage . as biogen approached the introduction of its first drug , the company found some areas of expertise were too costly or time - consuming to build internally . biogen turned to outside consultants for matters as diverse as strategic planning and systems implementation . and for one critical process , the company even tapped the expertise of large pharmaceutical companies .

biogen idec and fumapharm have been collaborating on a drug for multiple sclerosis and psoriasis , bg - 12 , since october 2003 . this agent has already cleared one phase iii study in psoriasis – a sector which biogen idec recently exited by selling off rights to its amevive ( alefacept ) treatment to japanese drugmaker astellas - with positive phase ii data in multiple sclerosis reported earlier this week .

biogen has expanded its operations through purchases of drug development firms , as well as by purchasing commercialized and development - stage drugs . in 2015 the company acquired uk - based convergence pharmaceuticals , a clinical - stage biopharmaceutical , for $ 200 . 1 million . the deal added convergence ' s cnv1014802 candidate ( for the treatment of trigeminal neuralgia and sciatica ) to biogen ' s pipeline .

on wednesday , biogen said u . s . tecfidera demand had stabilized , while sales were growing in europe , allowing for a renewed focus on the company’s promising stable of drugs in development .

so biogen had to raise money , cut expenses and build a senior management team . wall street had written off biogen , but mr . vincent ' s track record in his previous jobs gave the company a chance to have its proposals heard , said frederick frank , an investment banker with lehman brothers , who represented the company . mr . vincent ' s credibility , coupled with an innovative convertible preferred offering that allowed investors to receive a dividend that was sheltered from taxes by biogen ' s losses , allowed the company to raise $ 65 million in the tough market of 1986 .

still , dr . rastetter said combining product portfolios with biogen would allow idec to ' ' avoid the growing pains and fits and starts of organic growth , which is an arduous process . ' '

biogen is more focused than ever on the areas where we can have the greatest impact . we built our business by putting science and patients at the center of every decision and investment we make .

for any business , in any competitive industry , the transition from research organization to operating company is critical . james l . vincent , biogen ' s chairman , calls it " transforming knowledge into product . " like adolescence , this corporate coming of age is rarely painless or predictable ; at biogen , the challenge was heightened by a cash crisis brought on by the profligacy of its early management .

products in biogen ' s pipeline include the anti - lingo program for ms , ban2401 ( in collaboration with eisai ) for alzheimer ' s disease , and stx - 100 for idiopathic pulmonary fibrosis .

keith speights has no position in any stocks mentioned . the motley fool owns shares of and recommends biogen and ionis pharmaceuticals . the motley fool recommends bioverativ . the motley fool has a disclosure policy .

biogen idec is dedicated to pursuing the creativity of science . the company ' s products and development programs address a variety of key medical needs in the areas of oncology , neurology , dermatology and rheumatology .

with the filing of its application , which occupied 32 feet of shelf space , biogen entered a period of frenzied activity . complicating matters , the german partner that had supplied beta interferon for the clinical trials declared bankruptcy , forcing biogen to jump - start production in a pilot plant in cambridge , at a cost of $ 10 million , and requiring another level of f . d . a . approval .

given that the hemophilia products offered some financial stability and growth for biogen , there was some apprehension from analysts when biogen decided to toss them aside . at the time of the spin - out , for instance , leerink partners biotech analyst geoffrey porges called it a “somewhat surprising move , ” noting the hemophilia products were fast - growing drugs “buffering…the negative headwinds” facing the rest of biogen’s business and the company would “more or less tread water” until the aducanumab data in 2019 . rbc capital markets’ micahel yee predicted “some head - scratching amongst investors” who “want more growth and diversification , not less . ” others disagree .

biogen is enrolling patients in two late stage trials of aducanumab , the alzheimer’s disease drug that generated excitement last year with early data that demonstrated reduction in amyloid plaque in the brain and some cognitive improvement .

but while going outside for help with the heavy lifting , biogen ' s management also looked inside during this pivotal period . at many larger drug companies , the leading scientists have little to do with a molecule once it passes from discovery to the trial process and ultimately to market , as it ceases to be a matter of science and becomes an engineering problem and a marketing issue . not so at biogen .

another drug , ms treatment fampyra ( also known as ampyra ) , is sold in partnership with acorda therapeutics . biogen is also co - marketing zinbryta , another ms treatment , in the us with abbvie .

to be sure , there were twists and turns in biogen ' s road to commercialization that could occur only in a company balanced on the leading edge of science . but the company ' s successful navigation of that journey reflects many more pragmatic disciplines : the timely addition of senior management , the willingness to make tough decisions without flinching , the balancing of internal capabilities and outsourcing and an early devotion to customer service . within seven months of its introduction , biogen ' s first drug had captured more than a 50 percent share of its target market , and biogen is now the second largest independent biotech company , behind amgen inc .

during this same period , biogen ' s scientists zeroed in on two drug candidates . one , which was ultimately named hirulog , was an anticoagulant , meant to be given to heart patients to prevent blood clotting . the drug was meant to replace heparin , an older drug that is inexpensive and effective but has problematic side effects , including bleeding . biogen ' s scientists believed hirulog would be both safer and more effective .

limited resources meant biogen chose whenever possible to use off - the - shelf software , primarily from the oracle corporation , rather than build custom applications . one exception was " integrated customer , ' ' a custom database combining commercial third - party data with biogen ' s own sales figures . " that was very important for them , to get a picture of how the market was responding , " mr . kenneally said .

by design , biogen under scangos amassed a risky , neuroscience - focused pipeline including a group of experimental alzheimer’s drugs in mid - and - late stage testing . under his watch , biogen has restructured and cut a number of jobs to support its risk - heavy investments , halting preclinical work in a variety of other areas . in the meantime , its share price has been on a rollercoaster—from less than $ 50 when scangos joined to highs of over $ 475 in march 2015 to the roughly $ 275 it trades at today—as wall street grew frustrated at biogen’s hesitance to pull the trigger on a transformative acquisition that can offset its risk .

each company has a billion - dollar drug - - idec ' s rituxan for non - hodgkin ' s lymphoma and biogen ' s avonex for multiple sclerosis . each also has a second drug on the market . but those products - - idec ' s zevalin , also for lymphoma , and biogen ' s amevive , for psoriasis - - are off to somewhat slow starts and some analysts doubt they will become big sellers .

biogen idec signed a definitive agreement to acquire privately - held fumapharm , the companies announced wednesday . the transaction , which was approved by both companies ' boards , is expected to close within the next two months .

biogen has offices in the us , australia , canada , japan , the us , and several european countries . it has direct sales operations in about 30 countries and operates through distribution partners in another 60 countries .

biogen media contact : jason glashow , + 1 781 - 464 - 3260 public . affairs @ urltoken or investor contact : carlo tanzi , ph . d . , + 1 781 - 464 - 2442 ir @ urltoken

the war games persuaded biogen to price avonex the same as betaseron . a higher price might have created roadblocks for patients trying to get reimbursement from medicare and insurers unless avonex ' s superiority could be proved , which would be a scientifically onerous task . and a lower price was unlikely to generate enough additional volume to offset the lower profit margins . biogen executives say the war game proved a fairly accurate predictor of how berlex would compete .

biogen’s seven anaerobic digestion plants recycle a quarter of a million tonnes of food waste annually from supermarkets , food manufacturers , the hospitality industry and local authorities to produce 13mw of renewable energy and a nutrient - rich biofertiliser .

on the pipeline side , biogen is walking away from its plans to develop the oral multiple sclerosis drug tecfidera for the secondary - progressive form of the disease , cutting a phase ii lupus program targeting the tweak immune cell , and discontinuing some preclinical projects in immunology and fibrosis research , the company said . biogen is also abandoning its ambitions of getting the injectable drug tysabri approved for secondary - progressive ms after reporting negative phase iii results wednesday .

australia ' s csl limited also has a next - generation factor 9 replacement therapy in late - stage development . csl954 demonstrated a 92 hour half - life , putting it about halfway between biogen and novo ' s offerings .

our employees are vitally important to the success of our work in supporting patients . we empower our employees to build rewarding careers at biogen , driven by a culture of learning that inspires employees to reach higher and take initiative .

that increase for tysabri also comes with an asterisk . more than 60 % of the first - quarter sales increase for the drug stemmed from biogen receiving payment from the italian national medicines agency for tysabri sales in prior periods .

ibd ' s take : bioverativ isn ' t your typical biotech startup . it ' s profitable and aiming for $ 1 billion in sales this year . head to the new america for a deeper dive into the biogen spinoff .

the third late - stage candidate in biogen ' s pipeline is gazyva , which is already on the market for treating chronic lymphocytic leukemia . a phase 3 study is underway for the drug in targeting non - hodgkin ' s lymphoma ( nhl ) . as with ocrevus , though , roche owns the marketing rights for gazyva . approval for the drug in the nhl indication would be good news for biogen but not enough to offset problems for its ms franchise .

biogen executives told analysts on a call that the company hoped its ongoing direct - to - consumer tecfidera television campaign will reaccelerate u . s . growth , but it will be difficult to gauge the impact until later this year .

indeed , one reason the stocks dropped yesterday , analysts said , was that some investors had been hoping biogen would be acquired for a premium by a big pharmaceutical company and that genentech would acquire idec to gain full control of rituxan .

biogen idec said yesterday it will acquire convergence pharmaceuticals for up to $ 675 million . the buyer said its purchase was intended to speed up development of convergence’s pain drug portfolio—especially cnv1014802 , a phase ii candidate that has shown promising results .

throughout the year , we welcome students at all levels and from all backgrounds to bring their passion , persistence , creativity , collaboration and focus to biogen to work alongside employees as colleagues , tackling meaningful projects and shaping their career aspirations .

biogen is truly proud to have an incredible group of teams and individuals , who not only embody our brand philosophy , “ # beyourbest” – but also advocate a healthy lifestyle , and who have achieved great things in their respective fields .

yet those systems had to be up and running before the expected food and drug administration approval of avonex came through , so biogen turned to the computer sciences corporation , a consulting and systems integration company based in newton lower falls , mass . " they put on a biogen shirt , suited up and played , " mr . tobin said . " we started out without a contract , but at each level of detail of the project , they were right there . "

but biogen ' s management did count on it , sufficiently so that trials of avonex in hepatitis were suspended . this decision was as much strategic as medical , mr . tobin said . although avonex appeared to be a better drug for hepatitis than alpha interferon , it was only modestly so . moreover , hep - atitis is a huge market , primarily asia - based , where biogen would have to compete directly with its own far - larger marketing partner , schering plough .

one measure of the market ' s response took biogen by surprise . after avonex was introduced in the united states , large numbers of multiple sclerosis patients called the company directly , seeking advice . in most diseases , drug companies rarely have contact with patients . but biogen executives say m . s . primarily strikes relatively young , affluent and educated white women , and the loss of control associated with the disease seemed to prompt many patients to seek greater understanding of the drug .

in october 2003 , biogen idec licensed certain exclusive worldwide rights to develop and market bg - 12 , oral fumarate derivative with an immunomodulatory mechanism of action , from fumapharm . biogen idec and fumapharm are evaluating bg - 12 in a range of diseases , including ms and psoriasis . in april 2005 , the companies announced that the primary endpoint was met in a phase iii study designed to evaluate the efficacy and safety of bg - 12 in the treatment of moderate to severe psoriasis .

painful but necessary , the shrinkage reduced biogen ' s burn rate , that quaint term high - tech startups use for cash consumption . but with product revenues still a distant promise , biogen needed a revenue source more secure than its repeated sales of equity . so mr . vincent spent the latter half of 1986 and all of 1987 renegotiating the licensing deal the company had previously signed with schering plough , for the interferons , on more favorable terms . he also signed new deals with merck , smith kline beecham and abbott for the use of patented biogen discoveries in making hepatitis vaccines and diagnostic kits . the royalty stream , just $ 1 . 7 million a year in 1986 , grew to $ 150 million by 1996 .

the deal was particularly rapid considering bioverativ is a rookie on wall street . biogen spun off its hemophilia business into bioverativ in february . bioverativ will pay true north $ 400 million upfront with a potential for $ 425 million in milestone payments .

current and historical pe ratio for biogen ( biib ) from 2006 to 2018 . the price to earnings or pe ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share ( eps ) number . the pe ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure . the current pe ratio for biogen ( biib ) as of march 31 , 2018 is 15 . 78 .

the plan is to do away with about 830 jobs by the end of 2015 , biogen said , an effort designed to save roughly $ 250 million in 2016 and beyond . biogen is now " in the process of notifying employees " who are losing their jobs , the company said . the decision " was extremely difficult , " ceo george scangos said in a statement , " but we believe these actions are necessary to fulfill our mission of bringing important new medicines to patients . "

tnt009 could move bioverativ from " defensive posturing " over its hemophilia unit — spun off from biogen ( biib ) — to a narrative of " offensive opportunity , " schmidt said . he expects investors to focus on the sizing opportunity for tnt009 .

analysts had been concerned biogen would provide a forecast below expectations after cautious comments by management at the recent jp morgan healthcare conference . that followed a 2015 in which the company slashed tecfidera’s growth forecast midyear and later announced a cost - saving restructuring .

biogen ( $ biib ) is laying off 11 % of its workforce and pulling the plug on a handful of pipeline projects , cutting deep into its infrastructure amid mounting pressure and turning its attention to some high - risk r & d programs .

biogen idec and abbvie announced monday morning that their once - monthly multiple sclerosis drug daclizumab has cleared key hurdles in a phase iii study , setting the stage for a marketing pitch to regulatory authorities . for biogen idec ( $ biib ) , the phase iii success offers a chance to expand on its blockbuster ms franchise with an imperfect but potentially lucrative new drug with some troubling side effects . and abbvie ( $ abbv ) has already counted this therapy as one of its top late - stage prospects .

the name bioverativ “creates a clear connection to our biogen heritage and biotech focus , ” cox said in a statement tuesday . the new company , which will be based somewhere in the boston area , will trade on the nasdaq under the symbol bivv .

the value of the fumapharm deal has not been disclosed , but its comes after biogen idec pledged $ 250 million to buy cancer specialist conforma therapeutics earlier this month , and spent $ 660 million licensing several antibody drugs from protein design labs last august .

that stumble , plus the multiple side effects of betaseron , created an opening , and biogen seized the opportunity . biogen ' s scientists convinced mr . vincent and mr . tobin that avonex , which more closely mimicked the natural beta interferon protein than betaseron did , would both be more effective against multiple sclerosis and have fewer side effects than the chiron - berlex product . they designed a third clinical trial , intended to show that the drug actually slowed the progression of the disease rather than just reducing flareups .

please be on the lookout for fraudulent interview requests and job postings at the hands of an individual or entity who claims to be an employee of biogen . this fraudulent scheme relates to the unauthorized use of our company name . we consider this matter a crime and are working with law enforcement to combat this issue . please be advised that all legitimate correspondence from a biogen employee will come from " @ urltoken " email accounts . automated system response emails come from “ @ brassring . com” email addresses . there are no variations of these email addresses . biogen posts job openings on its website at urltoken if you are interested in any opportunities at biogen , please apply to current openings through our website . you will never be asked to download google hangouts or asked to submit banking information through unsecure means . if you believe that you may have been a victim of this fraud , we suggest you contact local law enforcement and actively monitor all financial accounts ; those steps may help mitigate any negative impact to your personal data .

shares of both companies fell about 5 percent on a day when the market was down over all . shares of biogen fell $ 2 . 25 , to $ 41 . 55 , while idec dropped $ 2 . 01 , to $ 36 . 96 .

in addition to gaining revenue from the development and sales of its products ( both directly and through partnerships ) , biogen receives royalties on some patents it has licensed to other companies . for instance , the medicines company pays royalties on sales of anticoagulant angiomax .

in early 2017 biogen spun off its growing hemophilia operations into a separate , publicly traded company named bioverativ . that business ' marketed products include eloctate and alprolix ; the new firm continues its activities around the discovery and development of hemophilia therapies utilizing xten technology .

biogen idec , the largest massachusetts - based biotechnology company , took the compound into clinical trials to test its effectiveness against ms at different dosage levels compared to placebos . the results from late - stage trials in 2011 turned out to be better than expected .

biogen and idec pharmaceuticals announced a merger yesterday that seemed to be taken from the big pharma playbook - - an effort to cut costs and broaden product pipelines , in part because each company could not develop products fast enough on its own to sustain rapid growth .

the experimental drug has shown clinical activity in proof of concept studies for trigeminal neuralgia ( tgn ) , and for treating pain associated with lumbosacral radiculopathy ( sciatica ) . the experimental drug has potential applicability in several other neuropathic pain states , according to biogen idec .

biogen , inc . is a biopharmaceutical company , which engages in discovering , developing , and delivering therapies for neurological and neurodegenerative diseases . it offers tecfidera , avonex , plegridy , tysabri , zinbryta , and fampyra for the treatment of multiple sclerosis ; . . .

biogen idec’s quest for an ms pill dates back to 2006 , when it bought privately held swiss drug maker fumapharm . in the process , the cambridge company acquired an experimental compound called bg - 12 being studied as an oral treatment for both ms and psoriasis .